Siglec-5/CD170 hFc Chimera, Human
Siglec-5/CD170 HFc Chimera, Human

The purity of Siglec-5/CD170 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

Siglec-5/CD170 HFc Chimera, Human

Siglec-5/CD170 hFc Chimera, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

Siglec-5/CD170 hFc Chimera, Human

Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding to PSGL1.
Z05825
¥48,501.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Siglec-5/CD170 (Glu17-Thr434)_x000D_
Accession # O15389		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 73.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 90-115 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • Siglec-5/CD170 HFc Chimera, Human
    • Siglec-5/CD170 HFc Chimera, Human

    The purity of Siglec-5/CD170 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • Siglec-5/CD170 HFc Chimera, Human
    • Siglec-5/CD170 HFc Chimera, Human

    Siglec-5/CD170 hFc Chimera, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.


Background
Target Background Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding to PSGL1.
Synonyms CD170; CD33 antigen-like 2; CD33L2; OBBP2; Siglec5; SIGLEC5; OB-BP2

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.